Jacobs Journal of Materials Science

Modification of Solid Lipid Nanoparticles for Drug Delivery

*Dr. Thao Truong Dinh Tran
Department Of Biomedical Engineering, International University, Ho Chi Minh City, Vietnam , Viet Nam

*Corresponding Author:
Dr. Thao Truong Dinh Tran
Department Of Biomedical Engineering, International University, Ho Chi Minh City, Vietnam , Viet Nam

Published on: 2018-05-03

Abstract

Solid lipid nanoparticles (SLNs) have been widely studied and considered as potential nano based-system in drug delivery. Composing of lipid components that are solid at room and body temperature, they have many desirable characteristics such as non-toxic nature, stability, biocompatibility and biodegradability, etc. For those reasons, SLNs have significantly attracted attention in pharmaceutical fields, especially, in the production, modification, and characterization using different techniques. Accordingly, this review provides an update on appropriate modification methods of SLNs, which can be listed as a sophisticated process on (1) surface modification including positive modification and targeting modification, (2) surfactant modification, and (3) lipid modification. Furthermore, future prospects and perspectives associated with SLNs will also be discussed in the scope of this review.

Keywords

Solid lipid nanoparticles; Positive charge; Surface modification; Positive modification; Modification for targeting; Surfactant modification; Lipid modification

Introduction

Recently, tremendous attention has been drawn on the progress of nano based-systems, which would optimize drug bioavailability [1-3]. Varieties of drug carrier systems such as polymeric nanoparticles, liposomes, magnetic nanoparticles, micelles, and solid lipid nanoparticles (SLNs) have been widely investigated [4-10]. Among those advanced strategies, SLNs have been reported to be a promising nanocarrier system that can enhance the bioavailability, permeability, solubility and stability of the drug loaded [11, 12]

SLNs were first studied in the 1990s as alternative colloidal systems to emulsions, liposomes, polymeric microparticles and nanoparticles [12]. They are submicron (50–1,000 nm) colloidal particles derived from oil-in-water emulsions by replacing liquid lipids with a lipid matrix that is solid at room temperature, in which drugs are dispersed and stabilized [13]. Generally, SLNs contain lipophilic or hydrophilic surfactants as stabilizers [14, 15], and physiologically tolerable lipid matrices solid at room temperature such as complex mixtures of purified triglycerides, glycerides, paraffin or even waxes [13, 16]. Due to their biocompatibility, biodegradability, physicochemical stability, and low cytotoxicity [12, 17, 18], SLNs are not only feasible for the incorporation of lipophilic and hydrophobic drugs but also able to enhance drug payload and stability [11], thereby facilitating the sustained release and controlled release of drugs. Moreover, SLNs can overcome the membrane stability and drug leaching problems of emulsions, or the toxicity problems of polymeric nanoparticles. SLNs also offer other unique characteristics such as small size, large surface area, high drug loading capacity, active interface interaction and possibility for large-scale production, which are all attractive in pharmaceutical fields [19]. 

Extensively, SLNs are attractive for targeted drug delivery applications and bioavailability enhancement via diverse routes, including oral, rectal, nasal, pulmonary, ocular, parenteral, and dermal routes, so on and so forth [20]. For parental route, they can be injected intravenously to circulate in the microvascular system and prevent macrophage uptake in the hydrophilic coating or can be used for gene delivery through electrostatic interactions and gene therapy in cancer treatment [16]. For oral route, SLNs granulates or powders can be encapsulated into capsules or pellets for investigation of oral administration [21]. For nasal and pulmonary delivery, SLNs could also be considered as effective colloidal with reducing the dosing frequency, improving drug bioavailability and diagnostics [21, 22]. 

Up to now, SLNs have been successfully used to enhance the bioavailability of poorly water-soluble drugs such as paclitaxel, cyclosporin A, etc. [13, 14, 23, 24]. Subsequently, with all the current advantages, they will continue to be widely studied as potential colloidal drug carriers compared to their polymeric counterparts and liposomes in targeting and delivering of drugs. SLNs are produced and then modified by various approaches in order to improve the efficiency of drugs incorporated. This review focuses on modification methods including surface modification, surfactant modification, and lipid modification.

Surface modification

Targeting modification

Among the nanoparticulate formulations, SLNs hold great potential advantages for site-specific drug delivery with small distribution and large surface areas. Therefore, SLNs can favorably modify its surface by functionalized groups [25-27]. Many researchers reported on alterations in the surface of SLNs by conjugating nanoparticles with specific substances such as ligands, antibodies, pH sensitive, magnetic agents and cations that specifically target tumor cells/ inflamed tissues or facilitate cellular uptake [25, 28-30]. Targeting drug delivery of SLNs to a specific organ, coupling with a sustained drug release profile would make SLNs an effective drug delivery system.

Kashanian et al. [31] proposed that the surface – modified SLN was prepared with the pH-sensitive carrier, N-glutaryl-phosphatidylethanolamine, as an outer shell to deliver triamcinolone acetonide to treat cancer and inflamed tissues in lymph nodes. The research reported that drug release from nanoparticles was found higher in the acidic condition. In another work, the targeted peptide ligand-coated SLN loaded with atorvastatin calcium (ATC) was fabricated by attaching the conjugated group of CSK peptide (CSKSSDYQC) and stearic acid with the beforehand manufactured ATC-loaded SLN [28]. The result showed that CSK peptide ligand-modified SLN had spherical shape, small particle size (150-160 nm), uniform distribution and high drug encapsulation efficiencies (around 80%) with sustained release behavior. The targeting modified SLN could improve drug absorption and facilitate the drug penetration across the intestinal mucosa. 

Recently, SLNs targeting drug delivery - the combination between inorganic magnetic nanoparticles and SLNs - found its applications in creating magnetic-guided SLNs for improving cancer therapy [32, 33]. In the research of Pang et al. [32], Ibuprofen-loaded magnetic SLN (Ib-MSLN) was prepared by the method of emulsification dispersion-ultrasonic. A lipophilic magnetic carrier (oleic acid-loaded Fe3 O4 ) incorporated with lipid phase containing Ibuprofen, was emulsified in an aqueous surfactant solution. The warm microemulsion was dispersed in cold water to form Ib-MSLN. Spherical shaped SLN with a mean diameter in the range 100-200 nm were obtained. The drug encapsulation efficiency was calculated about 86 % of drug entrapped in MSLN. The SEM and XRD pattern also indicated that magnetic nanoparticles were successfully embedded in SLN. Similarly, in the study published by Albuquerque et al [34], the multi-functionalized SLN was co-incorporated with Methotrexate (MTX) as therapy agent and superparamagnetic iron oxide nanoparticles (SPIONs) as contrast agent of MRI for rheumatoid arthritis (RA) diagnosis. The dual-encapsulation SLN system was then conjugated with anti-CD64 that could target the cell receptors presented in RA macrophages. The results showed that the encapsulation of SPIONs could alter the surface structure of lipid in the SLN, leading to the increase in nanoparticle size; in addition, the efficiency of MTX and SPIONs within SLN were higher than 98%. In another research, the SLN/siRNA complexes were successfully developed by Kong et al. [35] for specific treatment of the liver, the cationic SLN were prepared by modified emulsification and solvent evaporation of lipid components reassembled natural apolipoprotein-free of low-density lipoprotein (LDL) with PEG-coated and positively charged surfactant on the monolayer. These nanoparticles could mimic natural lipoproteins, which could interact with lipoprotein receptors such as LDL and remnant receptor that are located in the liver. Their bio-distribution evaluated by confocal microscopy, ex vivo fluorescence bio-imaging and single-photo emission computed tomography (SPECT) revealed that the cationic SLN/siRNA complexes were successfully delivered and attached to the liver. Therefore, the coating of nanoparticle with cationic lipid could allow the targeting of the drug to the specific parts of the body to improve drug efficacy and safety in therapeutic treatment.

Positive modification

Positively charged SLNs are promising genetic materials for intracellular gene delivery. The ionic interaction between nano molecules and cell membranes is important to open the cell pathway. Surfactants and cationic lipids are often used to modulate positive charge of the SLNs surface to enhance drug bioavailability and facilitate cellular uptake via electrostatic interactions [36, 37]. The cationic modified SLN was report ed in 2001 by Olbrich et al. [38], which was prepared by hot homogenization method using Compritol ATO 888 as lipid, Tween 80/Span 85 as surfactant and EQ1 as charged carrier. The modified SLN could form complexes with polyanionic DNA. The results also proposed that the binding effect between SLN and DNA was influenced by the compatibility of the lipid matrix and the domain hydrophobic modifier, affecting the association of the tension from the particle surface upon attachment to DNA. Other applications of positive modification SLNs have been developed actively; especially, cationic SLNs loaded with anticancer agents have been investigated. The positively charged SLNs coated by cationic surfactant can bind to cancer cells through the electrostatic interactions with negatively charged phospholipids that are overexpressed on the surface of the cancer cells [39-41]. A research by Hwang et al. [42] investigated the capability of cetyltrimethylammonium bromide as a cationic surfactant. These novel cationic modified SLNs containing cetyl palmitate, soybean phosphatidylcholine (lipid phase) and Pluronic F68 (aqueous phase) were fabricated by high-shear homogenization method. The results revealed that cationic SLNs could affect the immune system by the activation of the human polymorphonuclear neutrophil cells.

Cationic SLN loaded with Saquinavir which was developed by Kuo and Chen [43], investigating the influence of cationic lipid in increasing the entrapment efficiency of Saquinavir. The average diameter and zeta potential of Saquinavir-loaded SLNs were about 140-190 nm and 8-14.5 mV, respectively. Moreover, an increase in cationic lipids stearyl amine caused an increase in the diameter and a decrease in the zeta potential. The cationic SLN carrying Saquinavir also showed the sustained release behavior with no burst release in the early stage. Lately, cationic SLNs that provide cytoprotection against ultraviolet A (UVA) radiation damage and H2O2 have been studied [44]. The study reported that the number of hydrophobic tails of cationic lipids influenced the crystalline structure of particles, as well as affected the drug entrapment efficiency and in vitro release behavior. Cytoprotective study against UVA and H2 O2 in HaCaT cells indicated that the presence of cationic lipids resulted in a high intracellular uptake and exhibited an effective protection against UVA irradiation and H2 O2 .

 

More recently, the novel positively charged surface-modified SLN consisted of chitosan or hydroxylpropyl trimethyl ammonium chloride chitosan was proved to have the ability to improve the absorption of Docetaxel through significant cellular uptake in Caco-2 cells [36].

Surfactant modification

Various studies indicated the effectiveness of surfactant modification in SLNs fabrication using poloxamers, lecithins, polysorbates and polyethoxylated monoglycerides for further stabilizing SLNs [45]. The surface area of particles is related to the stability of colloid particles, accompanying with solidification during crystallization [46, 47]. In fact, surfactants supply better interface quality of nanoparticles to gain stable properties. Lecithin whose molecules existed as the form of bilayer membrane was chosen by Han et al. [53] for stabilizing nanostructured lipid carriers system, based on its properties which can balance particle surface. In this study, ionic surfactant showed significantly low emulsification efficiency, but non-ionic emulsifier poloxamer 188 (POX 188) with additional steric stabilization possessed fine particles, which helped to avoid aggregation in the system. The combination of POX 188 and lecithin also created a narrow size distribution that could be applied for PEG-modified SLN to improve the performance of nebivolol for hypertension treatment [54]. In another investigation of surfactant modification by Na et al. [55], the modified SLNs were prepared with WGA-N-glut-PE (wheat germ agglutinin-N-glutaryl-phosphatidylethanolamine) and showed that this system significantly promoted insulin absorption. Lipid modification Lipid is the main ingredient, which affects lipid nanoparticles drug loading capacity, stability, and the sustained release behavior. Several lipid materials comprising of fatty acids, fatty alcohol, triglycerides, glycerides, and waxes have been investigated. The influence of lipid matrices on drug encapsulation efficiency, loading capacities and the usefulness of lipid nanoparticles in drug delivery have also been studied [57]. The study of fabricated SLNs using fatty acid (stearic acid) revealed that as the lipid content increased, the entrapment efficiency was increased. Small particle size (around 500-700 nm) was also observed. Moreover, the high amount of lipid also prevented the drug diffusion from the internal phase to the external phase by increasing the viscosity of the system, leading to the faster solidification [58]. Another factor that affects the properties of lipid nanoparticle system is lipid polymorphism. The perfect crystalline form of the lattice which is thermodynamically stable is preferred to be produced rather than an appropriate lipid forming prefect crystalline lattice structure. The “nanostructure lipid carrier” was developed to avoid various problems [59, 60] of fatty acids and wax based lipid nanoparticles by combining two different solid lipid matrices [61-63]. Jun et al. [64] also developed an SLN system based on crystal structure and polymorphism with lattice defects by incorporating PEG 2000 into lipid matrix, which was distributed in SLN surface to increase the repulsion between nanoparticles and prevent aggregation. Surface steric hindrance of PEG2000 was highly maintained for stable nanoparticle size distribution of the system, which made it suitable for controlled release systems [64].

Conclusion and future perspective

The potential applications of solid lipid nanoparticles for drug delivery with loading capacity of various active compounds have attracted a lot of attentions in recent studies. The modified forms of SLNs such as lipid conjugation, targeted delivery SLNs, positively charged SLNs are emphasized by their advantages of biocompatibility, biodegradability, physicochemical stability, low cytotoxicity, targeting drug delivery, improved bioavailability and hence, cultivating the increasing importance of SLNs among tradition colloidal carriers. Although some multi-nanosystems based SLN upon dosage forms of SLN-loaded gels, creams, and emulsions have undertaken and showed evidence of advantageous delivery, which could enhance therapeutic effectiveness, the numbers of such studies do not sufficiently reflect versatile applications of this system. In the near future, more dual/multi-system basedSLNs are believed to be further developed to give a new insight into their drug delivery and controlled release applications. 

Acknowledgments

This research is funded by Vietnam National University – Ho Chi Minh City (VNU-HCM) under grant number C2016-28-03.  

References

  1. Ramalingam P, Ko YT. Enhanced oral delivery of curcumin from N-trimethyl chitosan surface-modified solid lipid nanoparticles: pharmacokinetic and brain distribution evaluations. Pharm Res. 2015, 32(2): 389-402.
  2. Tran TT, Tran KA, Tran PH. Modulation of particle size and molecular interactions by sonoprecipitation method for enhancing dissolution rate of poorly water-soluble drug. Ultrason Sonochem. 2015, 24: 256-263.
  3. Tran TT, Tran PH, Nguyen MN, Tran KT, Pham MN et al. Amorphous isradipine nanosuspension by the sonoprecipitation method. Int J Pharm. 2014, 474(1-2): 146-150.
  4. Chen D, Xia D, Li X, Zhu Q, Yu H et al. Comparative study of Pluronic® F127-modified liposomes and chitosan-modified liposomes for mucus penetration and oral absorption of cyclosporine A in rats. Int J Pharm. 2013, 449(1-2): 1-9.
  5. Mo R, Jin X, Li N, Ju C, Sun M. The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles. Biomaterials. 2011, 32(20): 4609-4620.
  6. Luo Y, Teng Z, Li Y, Wang Q. Solid lipid nanoparticles for oral drug delivery: chitosan coating improves stability, controlled delivery, mucoadhesion and cellular uptake. Carbohydr Polym. 2015, 122: 221-229.
  7. Tran PH, Tran TT, Vo TV. Polymer Conjugate-Based Nanomaterials for Drug Delivery. J Nanosci Nanotechnol. 2014, 14(1): 815-827.
  8. Tran PH, Tran TT, Vo TV, Vo CL, Lee BJ. Novel Multifunctional Biocompatible Gelatin-Oleic Acid Conjugate: Self-Assembled Nanoparticles for Drug Delivery. J Biomed Nanotechnol. 2013, 9(8): 1416-1431.
  9. Tran TT, Vo TV, Tran PH. Design of iron oxide nanoparticles decorated oleic acid and bovine serum albumin for drug delivery. Chem Eng Res Des. 2015, 94: 112-118.
  10. Phan UT, Nguyen KT, Vo TV, Duan W, Tran PH et al. Investigation of Fucoidan–Oleic Acid Conjugate for Delivery of Curcumin and Paclitaxel. Anti-Cancer Agents Med Chem. 2016, 16(10): 1281-1287.
  11. Mehnertand W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Advanced drug delivery reviews. 2001, 47(2-3): 165-196.
  12. MuÈller RH, MaÈder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery–a review of the state of the art. European journal of pharmaceutics and biopharmaceutics. 2000, 50(1): 161-177.
  13. Hu L, Tang X, Cui F. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmacol. 2004, 56(12): 1527-1535.
  14. Peltier S, Oger JM, Lagarce F, Couet W, Benoît JP. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm res. 2006, 23(6): 1243-1250.
  15. Dong X, Mattingly CA, Tseng MT, Cho MJ, Liu Y. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer res. 2009, 69(9): 3918-3926.
  16. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004, 56(9): 1257-1272.
  17. Shi LL, Cao Y, Zhu XY, Cui JH, Cao QR. Optimization of process variables of zanamivir-loaded solid lipid nanoparticles and the prediction of their cellular transport in Caco-2 cell model. Int J Pharm. 2015, 478(1): 60-69.
  18. Dong Y, Ng WK, Shen S, Kim S, Tan RB. Solid lipid nanoparticles: continuous and potential large-scale nanoprecipitation production in static mixers. Colloids Surf B Biointerfaces. 2012, 94: 68-72.
  19. Cavalli R, Caputo O, Gasco MR. Solid lipospheres of doxorubicin and idarubicin. International journal of pharmaceutics. 1993, 89(1): 9-12.
  20. Shah R, Eldridge D, Palombo E, Harding I. Lipid nanoparticles: Production, characterization and stability. Springer. 2015.
  21. Pinto J, Müller R. Pellets as carriers of solid lipid nanoparticles (SLN) for oral administration of drugs. Pharmazie. 1999,